Breast cancer drug developer emerges after a dozen years with $54M round

The company's Phase I/II study in metastatic breast cancer is its first clinical trial, and its looking for space to grow.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.